Terns Pharmaceuticals
About
Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global disease burden.
- Foster City,California,United States
- 11 - 50
- https://ternspharma.com/
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $86.30M
- Industries
- Biotechnology,Health Care,Medical,Medical Device,Pharmaceutical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Stock Symbol
- nasdaq:TERN
- Legal Name
- Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer.
The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets.
Based in San Mateo, California and Shanghai, Terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in China and globally.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 20, 2022 | Post-IPO Equity | $86.30M | — | — | — | Detail |
| Aug 12, 2022 | Post-IPO Equity | $65M | 2 |
Fairmount Funds Management
|
— | Detail |
| Feb 4, 2021 | IPO | $127.50M | — | — | — | Detail |
| Jan 5, 2021 | Series C | $87M | 7 |
Eli Lilly
|
— | Detail |
| Oct 30, 2018 | Series B | $80M | 4 |
OrbiMed
Vivo Capital
|
— | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Aug 17, 2021
1K Kirana Bazaar
|
Series A | ₹520M | Consumer | — |
|
Jul 18, 2021
Captain Fresh
|
Series A | ₹890M | B2B | — |
|
Mar 4, 2021
Agrim Wholesale
|
Seed | $2.40M | E-Commerce | — |
|
Jan 29, 2021
Saveo
|
Seed | ₹290M | E-Commerce | — |
|
Jul 15, 2020
Captain Fresh
|
Series A | $12M | B2B | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Fairmount Funds Management
|
Yes | Post-IPO Equity |
|
|
Yes | Post-IPO Equity |
|
|
Yes | Series C |
|
Eli Lilly
|
Yes | Series C |
Lilly Asia Ventures
|
— | Series C |
|
OrbiMed
|
— | Series C |
Samara Capital
|
— | Series C |
Suvretta Capital Management
|
— | Series C |
|
Vivo Capital
|
— | Series C |
Decheng Capital
|
— | Series B |
Employee Profiles
